Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial
Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients with NAFLD and constipation. The most common adverse event was dia...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
